Regeneron, Telix Target Solid Tumors in Radiopharma Partnership Worth Up to $2.14 Billion

Regeneron Pharmaceuticals and Australian-based Telix Pharmaceuticals today announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies under a 50/50 cost and profit-sharing model, the companies announced on April 13, 2026.¹ Under the collaboration, Telix will receive a $40 million upfront payment, with the potential for up to $2.1 billion in milestone payments.

Radiopharmaceuticals are rapidly growing into an important field for oncology therapy, and new partnerships are signaling a shift toward combining biologics expertise with targeted radiation delivery to improve precision and efficacy in solid tumors.²

The partnership will initially focus on four programs, with the option to expand, integrating Regeneron’s antibody platforms with Telix’s radiopharmaceutical development and manufacturing capabilities.

Why are radiopharmaceuticals gaining momentum in oncology pipelines?

Radiopharmaceuticals combine tumor-targeting molecules with radioactive isotopes to deliver localized cytotoxic effects. They offer a differentiated mechanism compared to traditional systemic therapies.² The collaboration will leverage antibodies generated from Regeneron’s antibody platform (VelocImmune) to precisely target tumor-associated antigens, paired with Telix’s expertise in radioligand design and supply chain infrastructure.

This convergence of biologics and radiation-based therapies reflects a broader industry trend toward modality combinations that enhance tumor specificity while limiting systemic toxicity.³ Radiopharmaceuticals are particularly attractive for solid tumors, for which targeted delivery remains a persistent challenge.²

“At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities—from monoclonal and bispecific antibodies to cell therapies and beyond,” said John Lin, MD, PhD, senior vice president of Oncology and Antibody Technology Research at Regeneron, in a company press release.¹ “Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need.”

How does this collaboration expand combination strategies in precision oncology?

Beyond therapeutic development, the Regeneron and Telix plan to co-develop diagnostic radiopharmaceuticals to support patient selection and treatment monitoring, which is becoming an increasingly critical component of precision oncology. These companion diagnostics can help identify patients most likely to benefit and enable real-time assessment of therapeutic response, according to the companies.

The collaboration also opens the door to combining radiopharmaceuticals with existing immunotherapy platforms, including Regeneron’s programmed cell death protein-1 inhibitor, particularly in high unmet need indications such as lung cancer. This approach aligns with a growing industry focus on multimodal treatment regimens that integrate targeted therapies, immunotherapy, and novel delivery systems.⁴

“Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform,” said Israel Lowy, MD, PhD, senior vice president, clinical development unit head, Oncology, Regeneron, in the release.¹

What does this deal signal for competition in radiopharmaceuticals and targeted therapies?

This agreement reflects how competition is increasing to build end-to-end capabilities in radiopharmaceuticals, including manufacturing and global supply chains,which have historically been bottlenecks for this modality.⁵ By combining Regeneron’s antibody discovery engine with Telix’s radiopharmaceutical infrastructure, the partnership aims to accelerate development timelines while expanding therapeutic options across multiple solid tumor types.

“The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients,” said Christian Behrenbruch, PhD, managing director and group CEO, Telix, in the release.¹

As radiopharmaceuticals gain traction alongside ADCs and other targeted modalities, this collaboration highlights a broader industry shift toward integrating diverse technologies to improve tumor targeting, patient selection, and clinical outcomes.^1,2

References

1. Regeneron Pharmaceuticals. Regeneron and Telix announce strategic radiopharma collaboration. Published April 13, 2026. Accessed April 13, 2026. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-telix-announce-strategic-radiopharma-collaboration
2. Zhang S, Wang X, Gao X, et al. Radiopharmaceuticals and their applications in medicine. Signal Transduction Targeted Ther. 2025;10:1. doi: 10.1038/s41392-024-02041-6
3. Tepper J, Sartor C. Radiation therapy and biologics: a ripe opportunity?. Nat. Rev. Clin. Oncol. 2006;3:463. doi: 10.1038/ncponc0565
4. Yang M, Olaoba OT, Zhang C, et al. Cancer immunotherapy and delivery system: An update. Pharmaceutics. 2022;14(8):1630. doi: 10.3390/pharmaceutics14081630
5. Alira Health. Navigating the evolving global nuclear medicine supply chain in 2025 and beyond. Published May 2025. Accessed April 13, 2026. https://alirahealth.com/wp-content/uploads/Navigating-the-Evolving-Global-Nuclear-Medicine-Supply-Chain-in-2025-and-Beyond.pdf